Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Altitude Group 20p £14.5m (ALT.L) The end-to-end solutions provider for branded merchandise reports FY results to March 2025.</li>
<li>Revenues increased 23.5% to $7.1m with an 8.6% increase in gross profit to $14.2m and PBT of $1.6m up from $1.4m.</li>
<li>The cash reduced to $0.7m from $1.5m following increasing investment for growth. </li>
</ul>


Altitude Group 20p £14.5m (ALT.L) The end-to-end solutions provider for branded merchandise reports FY results to March 2025.
Revenues increased 23.5% to $7.1m with an 8.6% increase in gross profit to $14.2m and PBT of $1.6m up from $1.4m.
The cash reduced to $0.7m from $1.5m following increasing investment for growth. 


<ul>
<li>The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.</li>
<li>The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.</li>
<li>The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. </li>
</ul>


The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.
The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.
The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. 


United Kingdom

Empresaria Group plc provides staffing and recruitment services in the United Kingdom, Continental Europe, and internationally. It offers permanent, temporary, and offshore recruitment services, as well as training services. The company primarily serves technical and industrial; IT, digital, and design; professional services; retail; executive search; healthcare; and other sectors. Empresaria Group plc was founded in 1996 and is based in Crawley, the United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Empresaria (EMR LN)

Hybridan Small Cap Feast: 07/08/2025

Altitude Group 20p £14.5m (ALT.L) The end-to-end solutions provider for branded merchandise reports FY results to March 2025.

Hybridan

Hybridan Small Cap Feast: 27/03/2025

The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)